(138) have previously shown that IL-22 could enhance CRC cell stemness and tumorigenic potential by upregulating core stem cell genes that relied on a STAT-3-dependent pathway, and pretreatment with anti-IL-22 antibody could significantly suppress tumor development and growth in mice after the subcutaneous injection of primary colon cancer cells. The gene discussed is IL22; the disease is malignant colon neoplasm.